Research programme: VEGF gene therapy - Ark TherapeuticsAlternative Names: Ad VEGF-D variants; EG013
Latest Information Update: 23 Nov 2012
At a glance
- Originator Ark Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Fetal growth retardation